REPLIMUNE GROUP INC's ticker is REPL and the CUSIP is 76029N106. A total of 99 filers reported holding REPLIMUNE GROUP INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,649,644 | +44.2% | 405,516 | +30.9% | 0.00% | – |
| Q1 2024 | $2,530,895 | +21.7% | 309,779 | +25.6% | 0.00% | – |
| Q4 2023 | $2,079,040 | -53.5% | 246,624 | -5.6% | 0.00% | -100.0% |
| Q3 2023 | $4,470,450 | -7.7% | 261,277 | +25.2% | 0.00% | 0.0% |
| Q2 2023 | $4,844,713 | +89.0% | 208,644 | +43.7% | 0.00% | 0.0% |
| Q1 2023 | $2,563,278 | -66.9% | 145,146 | -48.9% | 0.00% | -50.0% |
| Q4 2022 | $7,733,096 | +1592.1% | 284,305 | +974.3% | 0.00% | – |
| Q3 2022 | $457,000 | -41.6% | 26,463 | -40.9% | 0.00% | – |
| Q2 2022 | $782,000 | +2.9% | 44,759 | 0.0% | 0.00% | – |
| Q1 2022 | $760,000 | -88.6% | 44,759 | -81.7% | 0.00% | -100.0% |
| Q4 2021 | $6,646,000 | -38.7% | 245,251 | -33.0% | 0.00% | -50.0% |
| Q3 2021 | $10,849,000 | -23.0% | 366,009 | -0.1% | 0.00% | 0.0% |
| Q2 2021 | $14,081,000 | – | 366,502 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 4,763,380 | $129,088,000 | 18.25% |
| Atlas Venture Life Science Advisors, LLC | 3,209,627 | $86,981,000 | 7.99% |
| Redmile Group, LLC | 3,866,512 | $104,782,000 | 2.38% |
| FRAZIER MANAGEMENT LLC | 650,862 | $17,638,000 | 1.36% |
| Mesirow Financial Investment Management, Inc. | 15,326 | $415,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,075,464 | $29,145,000 | 1.03% |
| EMERALD ADVISERS, LLC | 989,958 | $26,828,000 | 0.99% |
| BVF INC/IL | 926,529 | $25,109,000 | 0.91% |
| Integral Health Asset Management, LLC | 100,000 | $2,710,000 | 0.75% |
| Artal Group S.A. | 900,000 | $24,390,000 | 0.66% |